Navigation Links
Codexis, Raizen to Develop First Generation Ethanol
Date:9/27/2011

REDWOOD CITY, Calif. and SAO PAULO, Sept. 27, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) and Raizen Energia S.A. today announced the signing of a joint development agreement to develop an improved first generation ethanol process with enhanced performance economics. Raizen is Brazil's largest sugar and ethanol producer.  

Under the terms of the agreement, Raizen and Codexis will deploy the Codexis CodeEvolver™ directed evolution technology platform to improve Raizen's current process for producing ethanol made from sugar.  Raizen produced 600 million gallons of ethanol in 2010.  The agreement focuses on a range of targets, including improving performance of yeasts now used in ethanol production.  The parties anticipate pilot production at Raizen's Bonfim mill.

Codexis will retain commercialization rights and Raizen will receive preferential commercial terms.  Successful developments under the collaboration will be covered by subsequent agreements. The collaboration may also include development of other products from sugar such as biobased chemicals.

Brazil is the world's second largest producer and consumer of ethanol, with 2010 production of 7 billion gallons.  Brazil is currently importing ethanol as a result of rising demand and lower current-season yields.  

"This agreement is very timely, since sugarcane ethanol in Brazil clearly needs to continue improving productivity to achieve expected yields in the years to come. Raizen and Codexis strongly believe that investing in technology is a critical path to achieve this," said Vasco Diaz, Raizen Chief Executive Officer.

"We are delighted to announce our first agreement with Raizen. Working together, we expect to quickly improve the performance and cost structure of first generation ethanol, now in use throughout Brazil.  We look forward to a productive and long term development partnership," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.  

About Raizen

Raizen is a $12 billion joint venture between Shell and Cosan, with annual production capacity of over 2 billion liters of ethanol, making it the third-largest fuels company in Brazil. It has a retail network of 4,500 fuel stations, 24 sugar mills and an installed capacity of 900MW of electric energy from sugar cane bagasse.

About Codexis

Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell, biobased chemicals and carbon capture. For more information, visit www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis' opportunities to improve the performance and cost structure of first generation ethanol with Raizen. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:  
Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771
Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331

Raizen: Carolina Landulfo, carolina.landulfo@maquina.inf.br, 55.11.3147.7400.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Codexis, Inc. Announces Pricing of Initial Public Offering
3. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Promising Cystic Fibrosis Compound on Track for Development
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
11. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):